Bovine interferon lambda Is a potent antiviral against SARS-CoV-2 infection in vitro

Interferon lambda (IFN-λ) is an antiviral naturally produced in response to viral infections, with activity on cells of epithelial origin and located in the mucosal surfaces. This localized activity results in reduced toxicity compared to type I IFNs, whose receptors are ubiquitously expressed. IFN-...

Full description

Bibliographic Details
Main Authors: Cardoso, Nancy, Mansilla, Florencia Celeste, Benedetti, Estefanía, Turco, Cecilia Soledad, Barone, Lucas Jose, Iserte, Javier Alonso, Soria, Ivana, Baumeister, Elsa, Capozzo, Alejandra
Format: info:ar-repo/semantics/artículo
Language:Inglés
Published: Frontiers Media 2021
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fvets.2020.603622/full
http://hdl.handle.net/20.500.12123/8588
https://doi.org/10.3389/fvets.2020.603622
_version_ 1855036063561547776
author Cardoso, Nancy
Mansilla, Florencia Celeste
Benedetti, Estefanía
Turco, Cecilia Soledad
Barone, Lucas Jose
Iserte, Javier Alonso
Soria, Ivana
Baumeister, Elsa
Capozzo, Alejandra
author_browse Barone, Lucas Jose
Baumeister, Elsa
Benedetti, Estefanía
Capozzo, Alejandra
Cardoso, Nancy
Iserte, Javier Alonso
Mansilla, Florencia Celeste
Soria, Ivana
Turco, Cecilia Soledad
author_facet Cardoso, Nancy
Mansilla, Florencia Celeste
Benedetti, Estefanía
Turco, Cecilia Soledad
Barone, Lucas Jose
Iserte, Javier Alonso
Soria, Ivana
Baumeister, Elsa
Capozzo, Alejandra
author_sort Cardoso, Nancy
collection INTA Digital
description Interferon lambda (IFN-λ) is an antiviral naturally produced in response to viral infections, with activity on cells of epithelial origin and located in the mucosal surfaces. This localized activity results in reduced toxicity compared to type I IFNs, whose receptors are ubiquitously expressed. IFN-λ has been effective in the therapy of respiratory viral infections, playing a crucial role in potentiating adaptive immune responses that initiate at mucosal surfaces. Human IFN-λ has polymorphisms that may cause differences in the interaction with the specific receptor in the human population. Interestingly, bovine IFN-λ3 has an in silico-predicted higher affinity for the human receptor than its human counterparts, with high identity with different human IFN-λ variants, making it a suitable antiviral therapeutic candidate for human health. Here, we demonstrate that a recombinant bovine IFN-λ (rbIFN-λ) produced in HEK-293 cells is effective in preventing SARS-CoV-2 infection of VERO cells, with an inhibitory concentration 50% (IC50) between 30 and 50 times lower than that of human type I IFN tested here (α2b and β1a). We also demonstrated the absence of toxicity of rbIFN-λ in human PBMCs and the lack of proinflammatory activity on these cells. Altogether, our results show that rbIFN-λ is as an effective antiviral potentially suitable for COVID-19 therapy. Among other potential applications, rbIFN-λ could be useful to preclude virus dispersion to the lungs and/or to reduce transmission from infected people. Moreover, and due to the non-specific activity of this IFN, it can be potentially effective against other respiratory viruses that may be circulating together with SARS-CoV-2.
format info:ar-repo/semantics/artículo
id INTA8588
institution Instituto Nacional de Tecnología Agropecuaria (INTA -Argentina)
language Inglés
publishDate 2021
publishDateRange 2021
publishDateSort 2021
publisher Frontiers Media
publisherStr Frontiers Media
record_format dspace
spelling INTA85882023-07-05T17:40:05Z Bovine interferon lambda Is a potent antiviral against SARS-CoV-2 infection in vitro Cardoso, Nancy Mansilla, Florencia Celeste Benedetti, Estefanía Turco, Cecilia Soledad Barone, Lucas Jose Iserte, Javier Alonso Soria, Ivana Baumeister, Elsa Capozzo, Alejandra COVID-19 Interferonas Viricidas Virus Interferons Antiviral Agents Viruses In vitro Interferon lambda (IFN-λ) is an antiviral naturally produced in response to viral infections, with activity on cells of epithelial origin and located in the mucosal surfaces. This localized activity results in reduced toxicity compared to type I IFNs, whose receptors are ubiquitously expressed. IFN-λ has been effective in the therapy of respiratory viral infections, playing a crucial role in potentiating adaptive immune responses that initiate at mucosal surfaces. Human IFN-λ has polymorphisms that may cause differences in the interaction with the specific receptor in the human population. Interestingly, bovine IFN-λ3 has an in silico-predicted higher affinity for the human receptor than its human counterparts, with high identity with different human IFN-λ variants, making it a suitable antiviral therapeutic candidate for human health. Here, we demonstrate that a recombinant bovine IFN-λ (rbIFN-λ) produced in HEK-293 cells is effective in preventing SARS-CoV-2 infection of VERO cells, with an inhibitory concentration 50% (IC50) between 30 and 50 times lower than that of human type I IFN tested here (α2b and β1a). We also demonstrated the absence of toxicity of rbIFN-λ in human PBMCs and the lack of proinflammatory activity on these cells. Altogether, our results show that rbIFN-λ is as an effective antiviral potentially suitable for COVID-19 therapy. Among other potential applications, rbIFN-λ could be useful to preclude virus dispersion to the lungs and/or to reduce transmission from infected people. Moreover, and due to the non-specific activity of this IFN, it can be potentially effective against other respiratory viruses that may be circulating together with SARS-CoV-2. Instituto de Virología Fil: Cardoso, Nancy Patricia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Mansilla, Florencia Celeste. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Benedetti, Estefanía. Instituto Nacional de Enfermedades Infecciosas, INEI–ANLIS “Dr. Carlos G. Malbrán". Servicio Virosis Respiratorias; Argentina Fil: Turco Cecilia Soledad. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Barone, Lucas Jose. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Iserte, Javier Alonso. Fundación Instituto Leloir. Structural Bioinformatics Group; Argentina Fil: Soria, Ivana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Baumeister, Elsa. Instituto Nacional de Enfermedades Infecciosas, INEI–ANLIS “Dr. Carlos G. Malbrán". Servicio Virosis Respiratorias; Argentina Fil: Capozzo, Alejandra Victoria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina 2021-01-08T18:28:54Z 2021-01-08T18:28:54Z 2020-11 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion https://www.frontiersin.org/articles/10.3389/fvets.2020.603622/full http://hdl.handle.net/20.500.12123/8588 2297-1769 https://doi.org/10.3389/fvets.2020.603622 eng info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) application/pdf Frontiers Media Frontiers in Veterinary Science 7 : 603622 (Noviembre 2020)
spellingShingle COVID-19
Interferonas
Viricidas
Virus
Interferons
Antiviral Agents
Viruses
In vitro
Cardoso, Nancy
Mansilla, Florencia Celeste
Benedetti, Estefanía
Turco, Cecilia Soledad
Barone, Lucas Jose
Iserte, Javier Alonso
Soria, Ivana
Baumeister, Elsa
Capozzo, Alejandra
Bovine interferon lambda Is a potent antiviral against SARS-CoV-2 infection in vitro
title Bovine interferon lambda Is a potent antiviral against SARS-CoV-2 infection in vitro
title_full Bovine interferon lambda Is a potent antiviral against SARS-CoV-2 infection in vitro
title_fullStr Bovine interferon lambda Is a potent antiviral against SARS-CoV-2 infection in vitro
title_full_unstemmed Bovine interferon lambda Is a potent antiviral against SARS-CoV-2 infection in vitro
title_short Bovine interferon lambda Is a potent antiviral against SARS-CoV-2 infection in vitro
title_sort bovine interferon lambda is a potent antiviral against sars cov 2 infection in vitro
topic COVID-19
Interferonas
Viricidas
Virus
Interferons
Antiviral Agents
Viruses
In vitro
url https://www.frontiersin.org/articles/10.3389/fvets.2020.603622/full
http://hdl.handle.net/20.500.12123/8588
https://doi.org/10.3389/fvets.2020.603622
work_keys_str_mv AT cardosonancy bovineinterferonlambdaisapotentantiviralagainstsarscov2infectioninvitro
AT mansillaflorenciaceleste bovineinterferonlambdaisapotentantiviralagainstsarscov2infectioninvitro
AT benedettiestefania bovineinterferonlambdaisapotentantiviralagainstsarscov2infectioninvitro
AT turcoceciliasoledad bovineinterferonlambdaisapotentantiviralagainstsarscov2infectioninvitro
AT baronelucasjose bovineinterferonlambdaisapotentantiviralagainstsarscov2infectioninvitro
AT isertejavieralonso bovineinterferonlambdaisapotentantiviralagainstsarscov2infectioninvitro
AT soriaivana bovineinterferonlambdaisapotentantiviralagainstsarscov2infectioninvitro
AT baumeisterelsa bovineinterferonlambdaisapotentantiviralagainstsarscov2infectioninvitro
AT capozzoalejandra bovineinterferonlambdaisapotentantiviralagainstsarscov2infectioninvitro